Biotech

Sarepta Therapeutics (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, granted equity awards on January 31, 2018, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment …

Sarepta Therapeutics (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, granted equity awards on January 31, 2018, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to twenty individuals hired by Sarepta in January 2018. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

As quoted in the press release:

The employees received, in the aggregate, options to purchase 92,793 shares of Sarepta’s common stock. The options have an exercise price of $65.54 per share, which is equal to the closing price of Sarepta’s common stock on January 31, 2018.

Click here to read the full press release.

Featured

MARKETS

Markets
TSX21205.16-69.41
TSXV900.87+10.01
DOW35028.65-339.82
S&P 5004532.76-44.35
NASD14340.26-166.64
ASX7332.50-76.30

COMMODITIES

Commodities
Gold1840.87+2.46
Silver24.14+0.06
Copper4.50+0.03
Palladium2050.00+69.50
Platinum1040.50+23.50
Oil86.38-0.58
Heating Oil2.61-0.03
Natural Gas4.00-0.03

DOWNLOAD FREE REPORTS

×